COMMUNIQUÉS West-GlobeNewswire

Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
04/03/2024
Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today [...]
BioVie Inc. Announces Pricing of Public Offering
04/03/2024
CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
04/03/2024
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies 1-6 Nearly all [...]
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
04/03/2024
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer ’ s Disease VIVIAD Phase 2b study did not meet its primary and key secondary endpoints Varoglutamstat was [...]
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
04/03/2024
Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the [...]
Valneva fera une présentation lors des conférences investisseurs TD Cowen et Van Lanschot Kempen
04/03/2024
Saint-Herblain (France), 4 mars 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que des membres de son équipe dirigeante participeront à des conférences [...]
Coherus Completes Divestiture of Ophthalmology Franchise
04/03/2024
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ( [...]
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
04/03/2024
MEDIA RELEASE CIMERLI ® *, a ranibizumab biosimilar, is interchangeable with LUCENTIS ® ** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz [...]
Ibogaine By David Dardashti Announces Breakthrough Algorithm to Quantify Quantum Electrodynamics
03/03/2024
Unlocking a Comprehensive Understanding of the Electric Force MIAMI, March 03, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a leading technology platform, is pleased to announce the successful development of an [...]
Ibogaine by David Dardashti Creates Innovative Algorithm for Fentanyl Treatment
03/03/2024
BOSTON, March 03, 2024 (GLOBE NEWSWIRE) -- For those struggling with fentanyl addiction, Ibogaine by David Dardashti is revolutionizing the way the deadly opiate is treated. Fentanyl Treatment Ibogaine by David [...]
Ibogaine By David Dardashti Visits Ohio to Explore Economic Benefits
03/03/2024
Organization Visits Ohio to Learn of the Benefits of Legalizing Ibogaine for Opiate Addiction BOSTON, March 03, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, an organization focusing on providing ibogaine [...]
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
02/03/2024
NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially presented at the ESMO [...]
Malaysia Healthcare Travel Council Denies Allegations of Lack Of Direction in the Company
02/03/2024
KUALA LUMPUR, Malaysia, March 02, 2024 (GLOBE NEWSWIRE) -- Malaysia Healthcare Travel Council (MHTC) would like to refer to the news published by a local news organisation titled - “Malaysia Healthcare Travel Council in [...]
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
02/03/2024
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/03/2024
Company Announcement COPENHAGEN, Denmark; March 02, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2024
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small [...]
MacroGenics to Participate in Upcoming Investor Conferences
01/03/2024
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]
ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference
01/03/2024
SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/03/2024
DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe [...]

Pages